42 results about "Secondary hypoparathyroidism" patented technology

The present invention relates to kits for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism. The kit provides means to measure the level of a PTH agonist and a PTH antagonist in a patient, and it further provides means for administering a PTH suppressing therapeutic to the patient so as to reduce the level of a PTH agonist and minimize the level of parathyroid hormone antagonist.

The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or lanthanum hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The capsules of the present invention dissolve at a similar rate before and after storage. The oral pharmaceutical capsules of the present invention can be administered to treat a patient at risk for or suffering from hyperphosphatemia, at risk for or suffering from chronic kidney disease (CKD), at risk for or suffering from soft tissue calcification associated with CKD, or at risk for or suffering from secondary hyperparathyroidism.

A method of treating and preventing secondary hyperparathyroidism in CKD by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering 25-hydroxyvitamin D3 with or without 25-hydroxyvitamin D2 and, as necessary, 1,25-dihydroxyvitamin D2 as a Vitamin D hormone replacement therapy.

19-nor-vitamin D analogs having an additional dihydrofuran ring connecting the 3β-oxygen and carbon-2 of the A-ring of the analog, and pharmaceutical uses therefore, are described. These compounds exhibit selective in vitro and in vivo activities, making them therapeutic agents for the treatment or prophylaxis of autoimmune diseases, some types of cancers, metabolic bone diseases, osteomalacia, osteopenia, secondary hyperparathyroidism, psoriasis, or other skin diseases.

The invention relates to the technical field of calcitriol, in particular to an oral solution containing calcitriol and a preparation method of the oral solution, and the oral solution containing calcitriol comprises the following components in parts by weight: 0.290-0.305 part of calcitriol; 29.7 to 30.3 parts of butyl hydroxy anisole; 29.8 to 30.2 parts of butylated hydroxytoluene (BHM); and 299987 to 300012 parts of medium chain triglycerides. The preparation method of the oral solution containing calcitriol comprises the following steps: S100, weighing: turning on a yellow light lamp in a weighing room, weighing calcitriol, medium chain triglyceride, butylated hydroxyanisole and butylated hydroxytoluene according to parts by weight, and carrying out double-person rechecking; compared with the prior art, the oral solution containing calcitriol has the following beneficial effects that the oral solution containing calcitriol can make up the blank in the field of treating secondary hyperparathyroidism of patients with moderate to severe chronic renal failure before dialysis and follow-up metabolic bone diseases and hypoparathyroidism in domestic children medication, and the clinical requirements are met.

19-nor-vitamin D analogs having an additional dihydrofuran ring connecting the 3β-oxygen and carbon-2 of the A-ring of the analog, and pharmaceutical uses therefore, are described. These compounds exhibit selective in vitro and in vivo activities, making them therapeutic agents for the treatment or prophylaxis of autoimmune diseases, some types of cancers, metabolic bone diseases, osteomalacia, osteopenia, secondary hyperparathyroidism, psoriasis, or other skin diseases.

19-nor-vitamin D analogs having an additional dihydrofuran ring connecting the 1α-oxygen and carbon-2 of the A-ring of the analog, and pharmaceutical uses therefore, are described. These compounds exhibit selective in vitro and in vivo activities, making them therapeutic agents for the treatment or prophylaxis of autoimmune diseases, some types of cancers, secondary hyperparathyroidism, psoriasis, or other skin diseases.

According to the present invention, provided are a dihydropyridazine-3,5-dione derivative, a salt thereof, and solvates of the derivative and of the salt. Also provided are the following that contain any of said compounds as an active ingredient: a drug, a drug composition, a sodium-dependent phosphate transporter inhibitor, and a prophylactic and / or therapeutic agent as well as a prophylactic and / or therapeutic method for hyperphosphatemia, secondary hyperparathyroidism, and chronic renal failure.

Methods and compositions for reducing serum parathyroid levels in, for example, chronic kidney disease patients are disclosed. In these methods, an effective amount of a modified release formulation of 25 -hydroxy vitamin D is orally administered to a patient suffering from secondary hyperparathyroidism to lower the patient' s serum intact parathyroid hormone (iPTH) level, while avoiding a surge in serum total 25-hydroxy vitamin D.

Methods and compositions for reducing serum parathyroid levels in, for example, chronic kidney disease patients are disclosed. In these methods, an effective amount of a modified release formulation of 25 -hydroxy vitamin D is orally administered to a patient suffering from secondary hyperparathyroidism to lower the patient' s serum intact parathyroid hormone (iPTH) level, while avoiding a surge in serum total 25 -hydroxy vitamin D.

Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, suchas cinacalcet or a pharmaceutically acceptable salt thereof, and / or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and / or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.

The invention belongs to the field of medicinal chemistry, and in particular relates to a new crystal form A of docalciferol and a preparation method thereof. The invention also relates to a pharmaceutical composition containing the new crystal form A of docalciferol and its role in the treatment of osteoporosis Hyperparathyroidism or secondary hyperparathyroidism. The new crystal form A of docalciferol, using Cu-Kα radiation, X-ray powder diffraction at 2θ angles at 7.82, 8.51, 12.06, 13.01, 15.60, 17.05, 17.82, 18.71, 19.35, 20.06, There are diffraction peaks at 20.37, 20.62, 21.98, 22.68, 22.90, 23.81, and 24.79. At the same time, the invention also discloses a process improvement scheme for preparing high-purity doxercalciferol, which has simple steps, easy operation, short time consumption and low cost, and is very beneficial to large-scale industrial production.

The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or its hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The present invention also includes an oral pharmaceutical powder comprising lanthanum carbonate or lanthanum carbonate hydrate and a pharmaceutically acceptable excipient. The oral pharmaceutical capsules and powders of the present invention can be administered to treat a patient at risk of or suffering from hyperphosphatemia, at risk of or suffering from chronic kidney disease (CKD), at risk of or suffering from soft tissue calcification associated with CKD, or at risk of or suffering from secondary hyperparathyroidism.

Methods for treating vitamin D insufficiency and secondary hyperparathyroidism in patients having CKD comprising administering repeat doses of 25-hydroxyvitamin D are disclosed. The methods comprise administering 25-hydroxyvitamin D in an amount effective to safely raise the patient's serum 25-hydroxyvitamin D level to greater than 90 ng / ml and / or to control the patient's serum ratio of 25-hydroxyvitamin D to 24,25-dihydroxyvitamin D to less than 20.